Vaccines

Patient receiving vaccine
#Immunology / Virology & Vaccines #National Institute for Health Research #Phase I trial #Stablepharma #Vaccines

Fridge-free vaccine effective at 30°C for at least two years

The world-first trial of a fridge-free tetanus-diphtheria vaccine has produced encouraging results that could improve access worldwide to crucial treatments.   Around half of vaccines are wasted globally each year, according to the World Health Organization, because of temperature changes during storage and transport.  Fridge-free vaccines… Read More

#News #Trending News

#Alzheimer's #Brain cancer #Cardiovascular disease #Cholesterol #Colorectal cancer #Dementia #Ebola virus #Eli Lilly #Gene therapy #Genetic profiling #Immunology / Virology & Vaccines #Peptides #Stem cells #University of Reading #Vaccines

DDW Highlights: 2 June 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a UK group accelerated efforts to develop a vaccine for Ebolavirus. Elsewhere,… Read More

#Podcasts

#Alzheimer's #Brain cancer #Cardiovascular disease #Cholesterol #Colorectal cancer #Dementia #Ebola virus #Eli Lilly #Gene therapy #Genetic profiling #Immunology / Virology & Vaccines #Peptides #Stem cells #University of Reading #Vaccines

This week in Drug Discovery (25–29 May) 

News round-up for 25–29 May by Bruno Quinney, Content Team at DDW.  This week, a UK group has accelerated efforts to develop a vaccine for Ebolavirus. Elsewhere, significant findings in colorectal and brain cancer could shape future cancer treatments.  The top stories:    UK group steps… Read More

#News

Vaccine
#Breast cancer #Vaccines

Anixa and Cytovance partner to develop breast cancer vaccine 

Biotechnology company Anixa Biosciences has partnered with Cytovance Biologics to support the Phase II clinical trial of a breast cancer vaccine.  The vaccine, developed in collaboration with Cleveland Clinic, targets α-lactalbumin, a lactation-associated protein that is typically expressed only in breast tissue during lactation but which re-emerges in many forms of breast cancer.   By generating an immune response… Read More

#Business & Investment #News

European Commission
#European Commission #GSK #Respiratory syncytial virus #Vaccines

European Commission approves RSV vaccine 

The European Commission (EC) has approved a respiratory syncytial virus (RSV) vaccine for the treatment of adult patients with lower respiratory tract disease (LRTD) caused by RSV.  Arexy, an adjuvanted recombinant RSV vaccine developed by GSK, will now be available to adult patients in European countries. The treatment was previously approved… Read More

#News #Regulatory

#Canada #Cell and gene therapy #Clinical trial #Concussion #ELRIG #European Medicines Agency #Melanoma #Merck #Moderna #Oxeia Biopharmaceuticals #Regulatory #UK #Vaccines

DDW Highlights: 27 January 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, an innovative therapy showed encouraging results in tackling melanoma. Elsewhere, why is… Read More

#Podcasts

#Canada #Cell and gene therapy #Clinical trial #Concussion #ELRIG #European Medicines Agency #Melanoma #Merck #Moderna #Oxeia Biopharmaceuticals #Regulatory #UK #Vaccines

This week in Drug Discovery (19 – 23 January) 

News round-up for 19 – 23 January by Bruno Quinney, Content Team at DDW.  This week in DDW, innovative therapies have shown encouraging results in tackling melanoma and concussion. Elsewhere, a UK-Canadian partnership looks to advance vaccine technology.  The top stories:    Combination therapy could slash melanoma mortality… Read More

#News

Clinical trial
#Canada #UK #Vaccines

UK-Canadian partnership to advance vaccine technology 

A £750,000 ($1 million) global collaboration has been launched to advance next-generation vaccine technology.  iiDiagnostics (iiDX), a company formed by the Infection Innovation Consortium: iiCON, and Canadian biotech Eyam Health have launched a collaboration to bring forward Eyam Health’s novel vaccine technology using advanced automated organoid models.   This £750,000 ($1 million) international initiative will combine Eyam’s advanced vaccine design and… Read More

#Business & Investment #News

Vaccine
#Africa #University of Oxford #Vaccines

Oxford’s Lassa fever vaccine administered in trial 

The first volunteer has been dosed in a first-in-human trial of the Lassa vaccine, marking an unprecedented step towards treating Lassa fever.  The vaccine, developed by the University of Oxford, is being assessed for its safety and the immune response it triggers in volunteers. Thirty-one people aged… Read More

#News

#Cell Science #Drug discovery #Organoids #Protein #Stem cells #Vaccines

How new scientific approaches are accelerating R&D

This is the latest episode of the free DDW Narrated Podcast, called “How new scientific approaches are accelerating R&D”. The episode covers two articles written for DDW Volume 25, Issue 1, Winter 2023/24. The first article is called ‘Accelerating recombinant protein vaccine discovery’. In the… Read More

#Featured Podcasts #Podcasts

#Bacteria #Genome sequencing #Vaccines

Vaccine could be developed for H. influenzae bacteria, study shows 

Scientists believe a vaccine could be developed to tackle Haemophilus influenzae (H. influenzae) bacteria, which causes up to 200 million childhood infections each year.  An international team including researchers at the Wellcome Sanger Institute, the University of Oslo, the University of Oxford and the Shoklo Malaria Research Unit at Mahidol University in Thailand, found… Read More

#News

Mosquito
#Australia #Vaccines #Virology

New research paves way for yellow fever vaccine development 

Researchers have captured the first-ever high-resolution images of yellow fever virus (YFV), which could pave the way for vaccine design.  Scientists at the University of Queensland, Australia, revealed structural differences between the vaccine strain (YFV-17D) and the virulent, disease-causing strains of the virus. Researchers combined yellow fever’s structural… Read More

#News

#Drug discovery #Immunology #Vaccines #Virology

eBook – Accelerating drug discovery with rational design: Reducing time, cost, and risk with cryo-EM

This eBook highlights recent examples of how cryo-EM and structural insights are being used across various therapeutic modalities to advance drug discovery pipelines. Structure-based drugs have two times the rate of clinical success at 50% of preclinical time and cost. Download this eBook to see the impact of cryo-EM on:… Read More

#eBooks

#Antimicrobial resistance (AMR) #Biotech #Vaccines

A universal approach to vaccines 

DDW Editor Reece Armstrong speaks to Dr Neil Murray, CEO of Liverpool-based RenewVax, that is developing the first universal vaccine for invasive pneumococcal disease, as well as vaccines for other antimicrobial resistant bacterial infections.   RA: What’s the current unmet need in terms of preventing and treating pneumococcal disease?   NM:… Read More

#Exclusive Content

Vaccine
#Clinical trials #Drug development #Drug discovery #Vaccines

Developing a new targeted vaccine for Pneumococcal disease in Malawi 

Earlier this year, the Infection Innovation Consortium: iiCON and partners launched the first human challenge trial for a new vaccine for pneumococcal disease – marking a key milestone in a collaborative global project that is offering new hope in the fight against the disease. Professor Stephen Gordon, Director of Experimental… Read More

#Exclusive Content

#Vaccines

Vaccine patent applications hit record high, new data reveals

Global vaccine patent applications hit a record high in the year to June 2025, according to data from intellectual property law firm Mathys & Squire.  The total number of applications increased to 1220 from 1135 the previous year, a 7% increase on the previous year and a… Read More

#News